IFI44 Promotes Clear Cell Renal Cell Carcinoma Progression via PRDX1 and Predicts Poor Prognosis
1Department of Urology, Zhejiang Cancer Hospital, Hangzhou, P.R. China.
2The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, P.R. China.
3School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, P.R. China.
4Department of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, P.R. China.
5College of Pharmacy, Zhejiang University of Technology, Hangzhou, P.R. China.
6Cixi Biomedical Research Institute, Wenzhou Medical University, Wenzhou, P.R. China.
7The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, P.R. China.
8Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, P.R. China.
9Department of Urology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, P.R. China.
10Department of Ultrasound, Zhejiang Cancer Hospital, Hangzhou, P.R. China.
11Shengli Clinical College of Fujian Medical University, Fuzhou, P.R. China.
12Department of Urology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, P.R. China.
13The Graduate School of Fujian Medical University, Fuzhou, P.R. China.
14Department of Urology, Fujian Medical University Union Hospital, Fuzhou, P.R. China.
收起